Chiral Metabolite Analysis by LC-MS/MS - Creative Proteomics Metabolomics

Chiral Metabolomics — Why Enantiomer-Resolved Data Matters

Mirror-image metabolites are chemically identical but biologically distinct — D-2-hydroxyglutarate drives IDH-mutant tumors while L-2HG does not, and D-serine, not L-serine, activates the NMDA receptor. Standard metabolomics sums both isomers into one number, hiding the biologically active species behind its inactive counterpart. Researchers are left unable to distinguish oncometabolite from background, D-serine from L-serine, or microbial D-lactate from host lactate.

Chiral metabolite analysis by LC-MS/MS resolves this by quantifying each enantiomer separately:

Enantiomer-resolved panels: D/L-amino acids, D-2HG, and D/L-lactate reported as separate D and L concentrations plus the D/L ratio — the active isomer is never averaged away.
Dual separation strategy: Chiral stationary phase columns and chemical derivatization are selected per analyte class, giving robust resolution for both abundant and trace D-isomers.
Oncometabolite-ready: The D/L-2-hydroxyglutarate panel separates D-2HG from L-2HG with sub-ng/mL LLOQ — the resolution required for IDH-mutant tumor studies.
Racemization-controlled QC: Enantiopure spike controls in every batch verify that measured D/L ratios reflect your sample, not preparation artifacts.

Chiral Metabolite Detection Panels and Customization

Three complementary chiral panels cover the enantiomeric metabolites researchers ask about most, plus a customization path for additional chiral targets. Each panel reports per-isomer concentrations with the D/L ratio, using class-matched isotopically labeled internal standards and per-analyte multi-point calibration.

Chiral Amino Acid Panel (D/L-Enantiomers)

Analyte Class	Representative D/L Pairs	Biological Context
D-Serine and D-Aspartate	D/L-Serine, D/L-Aspartate	D-Serine: NMDA receptor co-agonist in schizophrenia, Alzheimer disease, and pain research; D-Aspartate: endocrine and neurodevelopmental signaling
Bacterial Cell Wall D-Amino Acids	D/L-Alanine, D/L-Glutamate, D/L-Proline	D-Ala and D-Glu are peptidoglycan components; gut microbiome D-amino acids modulate host immunity and satiety signaling
Aromatic and Branched-Chain D-Amino Acids	D/L-Phenylalanine, D/L-Tyrosine, D/L-Tryptophan, D/L-Valine, D/L-Leucine, D/L-Isoleucine	Dietary and microbial D-amino acids; racemization markers of protein aging and food processing
Additional Chiral Amino Acids	D/L-Methionine, D/L-Threonine (incl. allo-Thr), D/L-Arginine, D/L-Histidine, D/L-Lysine, D/L-Asn, D/L-Gln	Complete stereochemical coverage of proteinogenic amino acids for aging, kidney function, and metabolic studies

D/L-2-Hydroxyglutarate Panel (Oncometabolite)

Analyte	Isomer Pair	Biological Context
2-Hydroxyglutarate	D-2HG and L-2HG quantified separately	D-2HG is the IDH1/IDH2-mutant oncometabolite in glioma, AML, and cholangiocarcinoma; L-2HG arises from hydroxyacid-oxoacid transhydrogenase and hypoxic conditions. Enantiomer-resolved measurement distinguishes true oncometabolite accumulation from background
Related TCA Intermediates	Alpha-ketoglutarate, cis-aconitate, citrate (achiral, for pathway context)	IDH mutation shifts the TCA pool; contextual achiral intermediates support interpretation of the D/L-2HG readout

Chiral Organic Acid and Hydroxy Acid Panel

Analyte Class	Enantiomer Pair	Biological Context
Lactate	D/L-Lactate	D-Lactate is a bacterial fermentation product and marker of gut microbial metabolism and sepsis; L-lactate reflects host glycolysis. The D/L ratio distinguishes microbial from host origin
Hydroxybutyrate	D/L-3-Hydroxybutyrate	D-3-HB is the physiological ketone body; L-3-HB is a minor enantiomer. Chiral separation avoids overestimation of ketone bodies in metabolic studies
Additional Chiral Organic Acids	2-Hydroxyisovalerate, 2-Hydroxybutyrate, glycerate (D/L)	Branched-chain and glycolytic side products with enantiomer-specific metabolic origins

Customization and Add-ons

Additional chiral targets — including enantiomers of carnitine, amino acid derivatives, and drug metabolites — can be added to any panel on request. For the achiral breadth of amino acid and organic acid coverage, our amino acid analysis and organic acids analysis services quantify the full panel of non-chiral and summed analytes on the same sample types.

Why Choose Our Chiral Metabolite Analysis Service?

Enantiomer-Resolved, Not Summed
Every analyte is reported as separate D and L concentrations plus the D/L ratio. You never have to infer the active isomer from a total.
Dual Separation Strategy
Chiral column and derivatization approaches are selected per analyte class, giving robust resolution for both abundant and trace D-isomers.
Trace D-Isomer Sensitivity
Derivatization enrichment and optimized MRM reach low ng/mL per-isomer LLOQs, resolving D-isomers that are 2 to 3 orders of magnitude less abundant than their L-forms.
Oncometabolite-Ready D-2HG Panel
D-2HG and L-2HG are quantified separately with sub-ng/mL sensitivity — the resolution required for IDH-mutant tumor studies.
Racemization-Controlled QC
Enantiopure spike controls in every batch verify that measured D/L ratios reflect your sample, not preparation artifacts.
Collaborator-Ready Deliverables
Annotated enantiomer chromatograms, D/L ratio tables, and a methods appendix support clear communication to collaborators and reviewers.

Chiral LC-MS/MS Technology and Method Performance

Enantiomer separation is achieved by two complementary strategies selected per analyte class, both coupled to triple-quadrupole MS/MS for absolute quantification.

Parameter	Specification
Chiral column separation (CSP-LC)	Polysaccharide and macrocyclic antibiotic chiral stationary phases (e.g., Chiralpak, Chirobiotic) for underivatized D/L separation of organic acids and hydroxy acids; mobile phase optimized per analyte pair
Derivatization-based separation	Marfey's-type and chiral labeling reagents (e.g., dansyl chloride, o-phthaldialdehyde with chiral thiol) convert enantiomers to diastereomers resolvable on reversed-phase columns; used for amino acids and low-abundance D-isomers
Mass spectrometry	Scheduled MRM on SCIEX QTRAP 6500+ with ≥2 transitions per isomer and qualifier-ratio confirmation; retention time locked against enantiopure reference standards
Sensitivity	Per-isomer LLOQ in the low ng/mL range (amino acids, lactate); D-2HG LLOQ below 0.5 ng/mL in plasma to resolve oncometabolite accumulation from background
Quantification performance	R² ≥ 0.995 per enantiomer calibration; accuracy and precision within ±15 percent (±20 percent at LLOQ); D/L ratio precision documented per batch
QC and racemization control	Racemization monitored with enantiopure spike controls during extraction and derivatization; pooled QC every 8 injections; isotope-labeled internal standards added at extraction

Chiral column separation principle: D and L enantiomers resolved on chiral stationary phase

Chiral column separation principle: D and L enantiomers resolved on the chiral stationary phase with baseline-separated peaks.

SCIEX QTRAP 6500+

Triple quadrupole MRM for enantiomer quantification

Thermo Q Exactive Focus

High-resolution confirmation of chiral species

Agilent 7890B GC-MS

Chiral GC for volatile chiral analytes

Chiral Metabolite Analysis Workflow — A Step-by-Step Guide

Study Design and Panel Configuration

We select the chiral panel (amino acids, D/L-2HG, or organic acids) and the separation strategy (chiral column or derivatization) based on your analyte classes, matrix, and expected abundance of the D-isomer. Internal standard suite and data format are aligned to your research question.

Sample Preparation and Enantiomer Stabilization

Samples are extracted under cold, pH-controlled conditions with isotope-labeled internal standards spiked at extraction. Enantiopure racemization controls accompany every batch to verify that measured D/L ratios reflect biology, not preparation artifacts.

Chiral Separation and MRM Acquisition

Enantiomers are resolved on chiral stationary phases or as diastereomers after derivatization, then quantified by scheduled MRM with ≥2 transitions per isomer. Retention times are locked against enantiopure reference standards for unambiguous assignment.

Quantification and D/L Ratio Reporting

Per-isomer concentrations are calculated from multi-point calibration curves; the D/L ratio is computed per sample and reported with QC flags. Linearity, precision, ion ratio confirmation, and racemization controls are reviewed before release.

Data Delivery and Interpretation Support

The complete data package includes per-isomer quantitative tables, D/L ratios, calibration and QC reports, annotated enantiomer chromatograms, raw data files, and a methods appendix formatted for direct inclusion in your manuscript methods section.

How to Prepare and Submit Samples for Chiral Metabolomics

Sample Type	Minimum Amount	Preparation	Storage and Shipping
Plasma / Serum	≥ 50 µL per panel	Collect in EDTA tube, centrifuge at 4°C within 30 min, aliquot, avoid hemolysis. Fasting samples recommended for lactate and amino acid panels	−80°C; ship on dry ice
CSF	≥ 100 µL	Aliquot immediately after collection; minimize freeze-thaw cycles — D-serine and D-aspartate are stable but concentrations are low	−80°C; ship on dry ice
Tissue (brain, liver, tumor)	≥ 20 mg wet weight	Snap-freeze in liquid nitrogen immediately; record wet weight. For 2-HG analysis, avoid prolonged ischemia time which alters TCA intermediates	−80°C; ship on dry ice
Cell Pellets	≥ 1 × 10⁶ cells	Wash twice with cold PBS, centrifuge at 4°C, aspirate supernatant completely, snap-freeze pellet. Include medium blank for secreted D-amino acids	−80°C; ship on dry ice
Fermentation Broth / Food	≥ 200 µL (broth); ≥ 200 mg (solid)	Centrifuge broth to remove cells; homogenize solids. Record processing history — D/L-lactate and D-amino acid ratios shift with fermentation time	−20°C or −80°C; ship on dry ice

Critical Notes:

Chiral integrity is the top priority — racemization during extraction or storage creates false D-isomer signal. We apply enantiopure spike controls in every batch and flag any sample where racemization controls exceed threshold.
Amino acid racemization accelerates with heat and alkaline pH. Samples must be kept cold and neutral during preparation; do not use acidic protein precipitation for D/L-amino acid panels unless discussed during study design.
D-2HG is stable in frozen plasma but is altered by delayed processing of tumor tissue. Snap-freeze tissue within minutes of resection for oncometabolite quantification.

Deliverables: What You Receive from Chiral Metabolomics Analysis

Every project returns a data package built for decision-making: per-isomer absolute concentrations, D/L ratios, and full QC documentation.

Quantitative Data Tables (.xlsx/.csv)
Per-isomer concentrations (µM or ng/mL), D/L ratio per analyte per sample, QC flags, and calculated metabolic indices where applicable.

QA/QC Report
Calibration linearity per enantiomer, internal standard recovery, pooled QC RSD, racemization control results, batch trend plots.

Annotated Enantiomer Chromatograms
MRM chromatograms showing baseline-separated D and L peaks with retention time markers and transition assignments.

Raw Data Files
Vendor-native files (.wiff) and open formats (.mzML, .csv) upon request.

Methods Appendix
Chiral column and derivatization conditions, MRM transitions, calibration strategy — formatted for direct inclusion in your manuscript methods section.

Enantiomer-resolved MRM chromatogram showing baseline separation of D and L isomers with retention time annotation

Representative chiral MRM chromatogram: baseline-separated D- and L-enantiomer peaks with retention times and MRM transitions annotated.

D/L ratio comparison across control and treatment groups with significance markers

D/L ratio comparison between control and treatment groups: per-sample ratios with SD error bars (mean ± SD, n = 6).

Applications of Chiral Metabolomics

Enantiomer-resolved metabolomics supports researchers across disciplines where the D and L forms carry different biological meaning:

Tumor Metabolism and Oncometabolite Research — Quantify D-2HG versus L-2HG in IDH1/IDH2-mutant glioma, AML, and cholangiocarcinoma; track oncometabolite accumulation as a mechanistic and biomarker readout
Neuroscience and Neurodegeneration — Measure D-serine and D-aspartate in CSF, brain tissue, and plasma for NMDA receptor, schizophrenia, Alzheimer disease, and pain research
Microbiome-Host Signaling — Profile gut microbial D-amino acids and D/L-lactate in plasma and stool to study bacterial contributions to host metabolism and immunity
Food Science and Fermentation — Monitor D/L-lactate and D/L-amino acid ratios as quality markers of fermentation, spoilage, and food adulteration
Aging and Kidney Function — Track amino acid racemization and D-amino acid accumulation as markers of protein aging and renal dysfunction

For discovery-scale screening before targeted chiral quantification, our untargeted metabolomics service identifies candidate metabolite shifts that the chiral panels then resolve at the enantiomer level.

Case Study: Amino Acid and Neurotransmitter Metabolomics in DNAJC12-Associated Parkinson Disease

Central biogenic amine deficiency with concomitant exploratory behavioral deficits in Dnajc12 knock-out mice

Deng, I. B., Follett, J., Fox, J. D., Wall, S., and Farrer, M. J. | npj Parkinson's Disease, 2025, 11, 143

DOI: 10.1038/s41531-025-00991-4

Background

Pathogenic variants in DNAJC12, a co-chaperone of the aromatic amino acid hydroxylases, cause young-onset Parkinson disease and a spectrum of neurological phenotypes. Because DNAJC12 supports the enzymes that synthesize dopamine and serotonin, researchers needed a quantitative readout of amino acid precursors and neurotransmitter metabolism in a knock-out mouse model — the same analytical family our chiral amino acid panels extend to the enantiomer level.

Challenge: Quantify plasma free amino acids and striatal biogenic amines in Dnajc12 knock-out versus wild-type mice to define the metabolic consequences of DNAJC12 loss and its link to biogenic amine deficiency.

Analytical Approach

Plasma samples from knock-out and wild-type mice were analyzed for free amino acids and related metabolites by UPLC-MRM/MS at Creative Proteomics, using 41 isotope-labeled internal standards with dansyl chloride derivatization. Striatal biogenic amines (dopamine, serotonin, and their metabolites) were quantified by HPLC.

Key Findings

Metric	Finding
Plasma phenylalanine (Phe)	Markedly increased in knock-out mice: 71.51 versus 45.15 µM in wild-type
Plasma tyrosine and tryptophan	Unchanged — Phe elevation is selective, consistent with mild hyperphenylalaninemia
Striatal dopamine (DA)	Reduced: 43.70 versus 58.86 ng/mg in wild-type
Striatal DA metabolites	DOPAC 3.20 versus 5.62 ng/mg; HVA 4.05 versus 6.82 ng/mg
Striatal serotonin (5-HT)	Reduced: 5.71 versus 9.38 ng/mg; 5-HIAA 0.83 versus 3.49 ng/mg
Behavioral phenotype	Exploratory behavioral deficits in knock-out mice, consistent with biogenic amine deficiency

What This Means for Your Chiral Metabolite Research

Quantitative amino acid panels define metabolic consequences of genetic loss. The plasma Phe elevation identified the biochemical signature of DNAJC12 deficiency with 41 internal standards and per-analyte quantification. Our chiral amino acid panel delivers the same quantitative rigor, with the added ability to resolve D and L forms where isomer identity matters.
Precursor-product relationships connect amino acids to neuroactive amines. Phe feeds the tyrosine/dopamine and tryptophan/serotonin axes; measuring the precursor pool alongside the amine product is what made the mechanism visible. Enantiomer-resolved analysis adds the D-serine/D-aspartate dimension to the same neurotransmitter biology.
Isotope-dilution quantification is the foundation. 41 isotope-labeled internal standards gave unambiguous, matrix-corrected concentrations — the same strategy underpins our chiral panels, extended to each enantiomer.

Conclusion

This study demonstrates how quantitative amino acid and neurotransmitter metabolomics — the analytical family our chiral panels extend — reveals the metabolic signature of a genetic disorder with clinical relevance to Parkinson disease. Our chiral metabolite analysis service provides the same isotope-dilution rigor with enantiomer resolution, for studies where the D and L forms of a metabolite carry different biology.

What is chiral metabolomics and why does enantiomer separation matter?

Chiral metabolomics separates and quantifies mirror-image metabolite pairs (enantiomers) that standard methods report as a single summed value. Enantiomers share the same formula and mass but can have opposite biological activities — D-2-hydroxyglutarate is an oncometabolite while L-2HG is a normal intermediate, and D-serine activates the NMDA receptor while L-serine does not. Measuring each isomer separately is essential wherever the D and L forms carry different biological meaning.

Which metabolites can you analyze as enantiomers?

Our chiral panels cover D/L-amino acids (including D-serine, D-aspartate, D-alanine, D-glutamate, and the full proteinogenic set), D/L-2-hydroxyglutarate, D/L-lactate, D/L-3-hydroxybutyrate, and additional chiral organic acids such as 2-hydroxyisovalerate and 2-hydroxybutyrate. Panels are configured around your specific analytes and research question.

What chiral separation methods do you use?

We use two complementary strategies. Chiral stationary phase columns (polysaccharide or macrocyclic antibiotic phases) separate underivatized enantiomers directly, which is preferred for organic acids and hydroxy acids. For amino acids and trace D-isomers, chemical derivatization (Marfey's-type or chiral labeling reagents) converts enantiomers to diastereomers that resolve on standard reversed-phase columns with enhanced sensitivity.

Can you distinguish D-2HG from L-2HG in tumor samples for IDH diagnostics?

Yes. Our D/L-2-hydroxyglutarate panel quantifies the two enantiomers separately with sub-ng/mL LLOQ in plasma and tissue. This resolution distinguishes true D-2HG oncometabolite accumulation — which marks IDH1/IDH2-mutant tumors — from L-2HG background arising from hydroxyacid-oxoacid transhydrogenase activity or hypoxic conditions.

What is the sensitivity for trace D-amino acids in a high L-isomer background?

D-isomers in biological samples are typically 2 to 3 orders of magnitude less abundant than their L-forms. Our derivatization-based workflows enrich and stabilize D-isomers, and optimized MRM with ≥2 transitions per isomer reaches low ng/mL per-isomer LLOQs. Where D-serine or D-aspartate is the target in CSF, the D/L ratio is reported even at trace D concentrations.

Do you report D/L ratios, and how are they calculated?

Yes — every chiral analyte is reported as separate D and L concentrations plus the D/L ratio per sample. Ratios are calculated from the quantified per-isomer concentrations after isotope-dilution correction, so they reflect biological enantiomeric balance rather than matrix effects. D/L ratio precision is documented in the QC report.

What sample types and minimum input do you accept?

We validate plasma, serum, CSF, tissue (brain, liver, tumor), cell pellets, conditioned medium, fermentation broth, and food matrices. Minimum input is approximately 50 µL for plasma or serum, 100 µL for CSF, 20 mg for tissue, and 1 × 10⁶ cells per panel. Exact requirements depend on analyte abundance and are confirmed during study design.

How do you prevent racemization during extraction and storage?

Racemization — the conversion of one enantiomer into the other — would create false D-signal. We extract samples under cold, pH-controlled conditions, avoid heat and alkaline steps for amino acid panels, and run enantiopure spike controls in every batch. Samples are stored at −80°C and shipped on dry ice; any batch where racemization controls exceed threshold is flagged in the QC report.

Can chiral metabolomics be combined with standard achiral targeted metabolomics?

Yes. The chiral panels add the stereochemical dimension to our amino acid analysis and organic acids analysis services on the same sample types. For a complete picture, the same extract can be split — one portion for summed achiral panels, one for enantiomer-resolved quantification — so you get both total and D/L-resolved data from a single submission.

How is method performance validated for chiral analysis?

Each enantiomer is calibrated with its own multi-point curve using enantiopure standards, with isotope-labeled internal standards spiked at extraction. Validation covers linearity (R² ≥ 0.995), accuracy and precision within ±15 percent (±20 percent at LLOQ), ion ratio confirmation, retention time locking, carryover, and racemization controls. Full validation data are included in the data package.

Central biogenic amine deficiency with concomitant exploratory behavioral deficits in Dnajc12 knock-out mice

Deng, I. B., Follett, J., Fox, J. D., Wall, S., and Farrer, M. J.

Journal: npj Parkinson's Disease, 2025, 11, 143

Plasma free amino acids analyzed by UPLC-MRM/MS with 41 isotope-labeled internal standards. Dnajc12 knock-out mice showed markedly increased plasma phenylalanine with striatal dopamine and serotonin depletion, defining the metabolic signature of DNAJC12-associated Parkinson disease.

Cancer SLC43A2 alters T cell methionine metabolism and histone methylation

Bian, Y., Li, W., Kremer, D. M., et al.

Journal: Nature, 2020, 585, 277–282

Amino acid metabolism study in which tumor cells outcompete T cells for methionine via SLC43A2, impairing histone methylation and T cell immunity. Demonstrates quantitative amino acid analysis as a mechanistic readout in cancer immunology.

Reducing branched-chain amino acids improves cardiac stress response in mice by decreasing histone H3K23 propionylation

Yang, Z., He, M., Austin, J., Sayed, D., and Abdellatif, M.

Journal: Journal of Clinical Investigation, 2023, 133(22), e169399

Branched-chain amino acid metabolism linked to cardiac stress response through histone propionylation. Targeted amino acid quantification revealed BCAA-driven epigenetic remodeling in the failing heart.

Untargeted metabolomics reveal sex-specific and non-specific redox-modulating metabolites in kidneys following binge drinking

Rafferty, D., Martins De Carvalho, L., Sutter, M., et al.

Journal: Redox Experimental Medicine, 2023, 2023(1), e230005

Untargeted UPLC-ESI-TOF-MS metabolomics of kidney tissue in a binge-drinking mouse model, identifying sex-specific metabolic alterations including tryptophan and kynurenine pathway changes. Demonstrates discovery-to-targeted workflows around amino acid metabolism.